Assembly Biosciences ASMB Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Assembly Biosciences (ASMB) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $57.6M in Q1 2026.
- How has Assembly Biosciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- Assembly Biosciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale increased by 117.9% year-over-year, from $26.43M to $57.6M.
- What is the long-term trend for Assembly Biosciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 4 years (2021 to 2025), Assembly Biosciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a -9.7% compound annual growth rate (CAGR), from $175.2M to $116.43M.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.